Anti-NGF Compound Adds to Company’s Early-Stage Pain Care Pipeline ABBOTT PARK, Ill., Nov. 12 (HSMN NewsFeed) — Abbott (NYSE: ABT ) announced today a definitive agreement to acquire the global rights to PanGenetics BV’s PG110 fully humanized antibody…
Biopharmaceuticals, Acquisitions
Abbott, PanGenetics, Nerve Growth Factor

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain”
Leave a Comment